Lexicon bags FDA OK on lead drug for carcinoid syndrome, preps for a commercial launch
Lexicon Pharmaceuticals $LXRX has completed a marathon development program with an FDA approval of telotristat ethyl (which will be sold as Xermelo and was …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
